Sichenzia Ross Ference LLP Represents Genetic Technologies Limited in $5.1 Million Public Offering
Press Release – New York, NY – July 20, 2020 – Sichenzia Ross Ference LLP today announced that it represented Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, in a registered direct offering of 1,025,000 American Depositary Shares (the “ADSs”), each representing six hundred of the Company’s ordinary shares, at a purchase price of $5.00 per ADS, for gross proceeds of $5.1 million.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The offering was made pursuant to a shelf registration statement on Form F-3 (File No. 333-237152), previously filed with and declared effective by the U.S. Securities and Exchange Commission on March 13, 2020, and March 23, 2020, respectively.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin Ocasio, and Avital Perlman, counsel Jeffrey Cahlon, and associate Yian Pan.
- Litigation Paralegal - November 28, 2022
- Sichenzia Ross Ference to Sponsor Gravitas Securities 6th Annual Growth Conference - November 22, 2022
- Memorandum RE: Pay v. Performance Disclosure Rules - November 22, 2022